

Policy: MP161

Section: Medical Benefit Policy

Subject: Thermal Capsulorrhaphy

Applicable Lines of Business

Commercial	X	CHIP	X
Medicare	X	ACA	X
Medicaid	X		

I. Policy: Thermal Capsulorrhaphy

II. Purpose/Objective:

To provide a policy of coverage regarding Thermal Capsulorrhaphy

III. Responsibility:

- A. Medical Directors
- B. Medical Management Department

IV. Required Definitions

1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

V. Additional Definitions

Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

- a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
- b. provided for the diagnosis, and the direct care and treatment of the Member's condition, illness disease or injury;
- c. in accordance with current standards of good medical treatment practiced by the general medical community;
- d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

Medicaid Business Segment

Medically Necessary — A service, item, procedure, or level of care that is necessary for the proper treatment or management of an illness, injury, or disability is one that:

- Will, or is reasonably expected to, prevent the onset of an illness, condition, injury or disability.
- Will, or is reasonably expected to, reduce or ameliorate the physical, mental or developmental effects of an illness, condition, injury or disability.

- Will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for Members of the same age.

DESCRIPTION:

Thermal Capsulorrhaphy, also known as electrothermal therapy or capsular shrinkage, is proposed as a treatment for shoulder instability and cruciate ligament laxity. Radiofrequency or electrothermal energy is applied to the ligament theoretically causing collagen fibers to shrink and stabilize the joint.

EXCLUSIONS:

The Plan does **NOT** provide coverage for the use of thermal capsulorrhaphy in the treatment of capsular and/or ligamentous structures of the shoulder, or other joints including, but not limited to the wrist, ankle or knee because it is considered to be **unproven** and therefore **NOT COVERED**. The Geisinger Technology Assessment Committee evaluated this technology and concluded that there is insufficient evidence in the peer-reviewed published medical literature to establish the effectiveness of this test on health outcomes when compared to established tests or technologies.

Note: A complete description of the process by which a given technology or service is evaluated and determined to be experimental, investigational or unproven is outlined in **MP 15 - Experimental Investigational or Unproven Services or Treatment**.

Medicaid Business Segment:

Any requests for services, that do not meet criteria set in the PARP, may be evaluated on a case by case basis

CODING ASSOCIATED WITH: Thermal Capsulorrhaphy

The following codes are included below for informational purposes and may not be all inclusive. Inclusion of a procedure or device code(s) does not constitute or imply coverage nor does it imply or guarantee provider reimbursement. Coverage is determined by the member specific benefit plan document and any applicable laws regarding coverage of specific services. Please note that per Medicare coverage rules, only specific CPT/HCPCS Codes may be covered for the Medicare Business Segment. Please consult the CMS website at www.cms.gov or the local Medicare Administrative Carrier (MAC) for more information on Medicare coverage and coding requirements.

S2300 arthroscopy, shoulder, surgical; with thermally induced capsulorrhaphy
 29999- unlisted arthroscopic procedure
 23929 Unlisted procedure, shoulder

Current Procedural Terminology (CPT®) © American Medical Association: Chicago, IL

LINE OF BUSINESS:

Eligibility and contract specific benefits, limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy. For Medicare, applicable LCD's and NCD's will supercede this policy. For PA Medicaid Business segment, this policy applies as written.

REFERENCES:

Geisinger Technology Assessment Committee Triage Group. Thermal Capsulorrhaphy. August 2005.

Halbrecht J. Long-term Failure of Thermal Shrinkage for Laxity of the Anterior Cruciate Ligament American Journal of Sports Medicine 33:990. (2005)

Miniaci A, McBirnie J. Thermal Capsular Shrinkage for the Treatment of Multidirectional Instability of the Shoulder. The Journal of Bone and Joint Surgery 85:2283-2287 (2003)

Ritzman TF, Parker RD, Thermal Capsulorrhaphy of the Shoulder. Current Opinion in Orthopedics 13(4); 288-291, August 2002.

Levy O, Wilson M, Williams H, Bruguera JA, Dodenhoff R, Sforza G, Copeland S. Thermal Capsular Shrinkage for Shoulder Instability. Mid-term Longitudinal Outcome Study. J Bone Joint Surg Br. 2001 Jul; 83(5): 640-645.

Roach, Roberts, Rees. The Potential Benefit of Thermal Shrinkage for Lax Anterior Cruciate Ligaments.

Carter TR, Bailie DS, Edinger S, Radiofrequency Electrothermal Shrinkage of the Anterior Cruciate Ligament. The American Journal of Sports Medicine 30: 221-226 (2002).

Hayashi K, Markel M. Thermal Capsulorrhaphy Treatment of Shoulder Instability: Basic Science. *Clinical Orthopaedics and Related Research*. (390): 59-72, September 2001.

Winifred S. Hayes, Hayes INC online. Thermal Shrinkage for Cruciate Ligament Injury. Published April 9, 2003

Washington State Department of Labor and Industry, Health Technology Assessment. Thermal Shrinkage for the Treatment of Shoulder Instability and Anterior Cruciate Ligament Laxity June 3, 2003

Miniaci A, Codsí MJ. Thermal Capsulorrhaphy for the Treatment of Shoulder Instability. *Am J Sports Med* 2006;34(8):1356-1363.

Park HB, Yokota A, Gill HS, Rassi GE, McFarland EG. Revision surgery for failed thermal capsulorrhaphy. *Am J Sports Med* 2005 Sep;33(9):1321-6.

HTAIS Custom Hotline Response. Thermal Capsulorrhaphy (Shrinkage) for shoulder instability. ECRI (online)

Mohtadi NG, Kirkley A, Hollinshead RM, et al; Joint Orthopaedic Initiative for National Trials of the Shoulder-Canada. Electrothermal arthroscopic capsulorrhaphy: Old technology, new evidence. A multicenter randomized clinical trial. *J Shoulder Elbow Surg*. 2014;23(8):1171-1180

McRae S, Leiter J, Subramanian K, et al. Randomized controlled trial of arthroscopic electrothermal capsulorrhaphy with Bankart repair and isolated arthroscopic Bankart repair. *Knee Surg Sports Traumatol Arthrosc*. 2016; 24(2):414-421

Romero EC, Arias AA, Serrano DD, et al. Arthroscopic electrothermal collagen shrinkage for partial scapholunate ligament tears, isolated or with associated triangular fibrocartilage complex injuries: A prospective study. *Musculoskelet Surg* 2020; Mar 2

UpToDate Berkoff, D: Multidirectional instability of the shoulder. UpToDate; updated November, 2020

Ricks M, Belward P, Hargreaves D. Long-term results of arthroscopic capsular shrinkage for palmar midcarpal instability of the wrist. *J Wrist Surg*. 2021; 10(3):224-228

Crespo Romero E, Arias Arias A, Dominguez Serrano D, et al. Arthroscopic electrothermal collagen shrinkage for partial scapholunate ligament tears, isolated or with associated triangular fibrocartilage complex injuries: A prospective study. *Musculoskelet Surg*. 2021;105(2):189-194.

Ventura A, Borgo E, Terzaghi C, et al. A four-step approach improves long-term functional outcomes in patients suffering from chronic ankle instability: a retrospective study with a follow-up of 7-16 years. *Knee Surg Sports Traumatol Arthrosc*. 2021; 29(5):1612-1616.

Wharton RMH, Lindau TR, Oestreich K. Arthroscopic capsular shrinkage is safe and effective in the treatment of midcarpal instability in a pediatric population: a single-center experience of 51 cases. *J Wrist Surg*. 2022; 12(3):239-247.

This policy will be revised as necessary and reviewed no less than annually.

Devised: 9/05

Revised: 9/06; 10/09(Added key words); 8/24 (refine exclusion language)

Reviewed: 9/07, 9/08, 9/10, 9/11, 9/12, 9/13, 9/14, 9/15, 8/16, 8/17, 8/18, 8/19, 8/20, 8/21, 8/22, 8/23,

CMS UM Oversight Committee Approval: 12/23; 11/8/24

Geisinger Health Plan may refer collectively to health care coverage sponsors Geisinger Health Plan, Geisinger Quality Options, Inc., and Geisinger Indemnity Insurance Company, unless otherwise noted. Geisinger Health Plan is part of Geisinger, an integrated health care delivery and coverage organization.

Coverage for experimental or investigational treatments, services and procedures is specifically excluded under the member's certificate with Geisinger Health Plan. Unproven services outside of an approved clinical trial are also specifically excluded under the member's certificate with Geisinger Health

Plan. This policy does not expand coverage to services or items specifically excluded from coverage in the member's certificate with Geisinger Health Plan. Additional information can be found in MP015 Experimental, Investigational or Unproven Services.

Prior authorization and/or pre-certification requirements for services or items may apply. Pre-certification lists may be found in the member's contract specific benefit document. Prior authorization requirements can be found at <https://www.geisinger.org/health-plan/providers/ghp-clinical-policies>

Please be advised that the use of the logos, service marks or names of Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company on a marketing, press releases or any communication piece regarding the contents of this medical policy is strictly prohibited without the prior written consent of Geisinger Health Plan. Additionally, the above medical policy does not confer any endorsement by Geisinger Health Plan, Geisinger Quality Options, Inc. and Geisinger Indemnity Insurance Company regarding the medical service, medical device or medical lab test described under this medical policy.